Cerebral Amyloid Angiopathy (CAA)

24 October 2012 - 26 October 2012

Course language: English

The goal of the conference is to bring together the leading international experts in β-amyloid metabolism, vascular biology, neuropathology, stroke genetics, brain imaging, and the clinical manifestations of cerebrovascular disease to present and discuss cutting-edge data in this rapidly developing field. A special focus will be moving the field towards clinical trials of candidate disease-modifying treatments, in particular by establishing consensus on preclinical animal data and human biomarkers for CAA trials. Other topics of discussion will be early detection methods for presymptomatic CAA and the biological and clinical interactions between CAA and Alzheimer’s disease.

The atmosphere for discussion is anticipated to be informal and lively, with ample opportunities for forming new collaborations and relationships within the growing CAA scientific and clinical communities.

Objective

At the completion of this program, participants should be better able:

  • To discuss the pathogenesis of CAA and CAA-related brain injury in relation to cerebral amyloid deposition, based on information from human and animal model studies
  • To consider biomarkers of β-amyloid deposition in cerebral blood vessels versus brain parenchyma, using novel neuroimaging techniques
  • To discuss the relationship between familial and sporadic CAA and other hereditary conditions including familial Alzheimer disease
  • To discuss the state of the art of emerging therapies for CAA
  • To consider surrogate markers of disease that are instrumental in treatment trials in CAA

This will be the third international meeting to focus on cerebral amyloid angiopathy (CAA). The first was held in Reykjavik, Iceland in August 2007, the second in Los Angeles, California in May 2010, and the third will be organized in Leiden, the Netherlands. Leiden University Medical Center has a rich history in CAA research, having been the site where the first hereditary form of CAA associated with mutation of the β-amyloid precursor protein was identified and characterized.

Abstracts

Abstract submission can be done to boerhaavecongress-service@lumc.nl. (max. 300 words)
Deadline 14 September 2012. Please mention ‘CAA’ in the subject line.

Hotel accommodation

Hotel reservation, click here

Travel information

There is a direct train connection from Amsterdam Schiphol Airport to Leiden, train run every 15 minutes and it take 20 minutes to reach Leiden.

Info over Parking

Touristic information

Touristic information Leiden, click here
 

Target group

Neuroscience clinicians (neurologists, geriatricians, pathologists, radiologists, allied health professionals) and translational/basic researchers and biopharmaceutical investigators with an interest in amyloid, stroke, Alzheimer’s disease and brain aging.

Conference Directors

  • M.A. van Buchem, MD, PhD, Professor and Chief of Neuroradiology, Department of Leiden University Medical Center, Leiden, The Netherlands
  • S.M. Greenberg, MD, PhD, Professor of Neurology, Harvard Medical School, Director, Hemorrhagic Stroke Research, Massachusetts General Hospital, Stroke Research Center, Boston, Massachusetts, USA

Organizing committee

  • B.J. Bacskai
  • C. Cordonnier
  • W. van der Flier
  • J. Haan
  • M. Jucker
  • J.M. Lee
  • J. Montaner
  • W. van Nostrand
  • E. Smith
  • H.V. Vinters

Programme

CAA Meeting—Leiden 2012
 
Wednesday, October 24:
 
Registration and Coffee
8:30 – 9:30     
 
Opening Session
9:30 - 9:35       Welcome                                 Mark van Buchem
9:35 - 10:00     The story of HCHWA-D        Joost Haan
 
Session 1. Detecting CAA: amyloid imaging and other biomarkers
Moderator: Harry Vinters
10:00 – 11:30  Plenaries
               10:00 – 10:30  : Imaging (Mark van Buchem)
               10:30 – 11:00  : Biomarkers in plasma and CSF (Joan Montaner)
               11:00 – 11:30 : New agents for amyloid imaging (Greg Zipfel)
11:30 – 12:30  Submitted papers and/or short invited talks
 
12:30 – 2:00   Lunch and poster viewing
 
Session 2. CAA and Cerebrovascular Disease: markers and mechanisms
Moderator: Raj Kalaria
2:00 – 3:30      Plenaries
            2:00 – 2:20      : Epidemiology (Meike Vernooij)
            2:20 – 2:40      : Imaging (David Werring)
            2:40 – 3:00      : Animal models I (Brian Bacskai)
            3:00 – 3:20      : Animal models II (Masafumi Ihara)
 
3:30 – 4:00     Break
 
4:00 – 5:00     Submitted papers and/or short invited talks

5:00 – 6:00    Poster viewing and drinks 
 
Thursday, October 25:
 
Session 3. Hereditary CAA: lessons from DIAN and AD
Moderator: Wiesje van der Flier
8:30 – 10:00    Plenaries
             8:30 – 9:00      : Lessons from the Dominantly Inherited Alzheimer Network                                                (DIAN) (Randall Bateman)
             9:00 – 9:30      : Lessons from Alzheimer’s Disease (Reisa Sperling)
             9:30 – 10:00    : Lessons from animal models (Mathias Jucker)
 
10:00 – 10:30  Break and poster viewing
 
10:30 – 11:00  Questions & Answers
11:00 – 12:00  Submitted papers and/or short invited talks
 
12:00 – 1:30    Lunch, poster viewing and lunchtime workshop: Small Vessel Disease staging (Raj Kalaria) 
 
Session 4. Towards Treatment I: endpoints for animal studies
Moderator: Marcel Verbeek*
Session to be organized around formulating proposed guidelines for animal studies aimed at identifying candidate CAA treatments for phase I-II human trials.
1:30 – 3:00      Plenaries
             1:30 – 2:00      : Hemorrhages (Jin-Moo Lee)
             2:00 – 2:30      : Amyloid and inflammation (William Van Nostrand)
             2:30 – 3:00      : Physiologic markers (Cenk Ayata)
 
3:00 – 3:30     Break and poster viewing
 
3:30 – 5:00     Discussion (discussion leader: Lee)
 
7:00                 Dinner for registrants and faculty
                         
 
Friday, October 26:
 
Session 5. Towards Treatment II: endpoints for human studies
Moderators: Eric Smith
Session to be organized around formulating proposed guidelines for human phase II studies aimed at identifying candidate CAA treatments for phase III clinical trials.
8:30 – 10:00    Presentation, discussion
             8:30 – 9:00      : Physiologic endpoints (Steven Greenberg)
             9:00 – 9:30      : Hemorrhagic endpoints (Charlotte Cordonnier)
             9:30 – 10:00    : Cognitive endpoints (Julie Schneider)
 
10:00 – 10:30  Break and poster viewing
 
10:30 – 12:00  Discussion (discussion leader: Greenberg)
 
12:00                Adjourn

 

 



Accreditation

the European Accreditation Council for Continuing Medical Education (EACCME) 15 CME credits
Nederlandse Internisten Vereniging (NIV) 15 punten

Start date

24 October 2012

Location

Leiden University Medical Center, building 3
Lecture hall 6 (Burumazaal)
Hippocratespad 21
2333 ZD LEIDEN

Price

Registration fee: Physians and faculty € 450,00  
Registration fee: Allied Health Professionals, trainees and conference sponsors € 300,00  

Please note: fees increase after 14 September with € 100,-.

Options

  • Social Event
    • Social Event € 50,00

Terms and conditions

Cancellations

Cancellations should be done in writing to Boerhaave Congress Service: boerhaavecongress-service@lumc.nl.
Cancellations costs are € 50,- After 10 October the registration fee will be not be reimbursed.